Children’s Oncology Group Sarcoma Plans - PowerPoint PPT Presentation

children s oncology group sarcoma plans n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Children’s Oncology Group Sarcoma Plans PowerPoint Presentation
Download Presentation
Children’s Oncology Group Sarcoma Plans

play fullscreen
1 / 13
Children’s Oncology Group Sarcoma Plans
282 Views
Download Presentation
whitley
Download Presentation

Children’s Oncology Group Sarcoma Plans

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Children’s Oncology Group Sarcoma Plans Holcombe E. Grier MD For the Children’s Oncology Group

  2. Lots of Folks Involved • Bone Sarcoma Committee • Neyssa Marina- chair • Rich Gorlick- vice chair • Mark Bernstein- previous chair of bone sarcoma committee • Mark Krailo- biostatistician • Soft Tissue Sarcoma Committee • William Meyer- chair • Doug Hawkins- vice chair • James Anderson- biostatistician

  3. Plan: Present Upfront and Relapsed Trials for Following Diseases • Bone tumors • Osteosarcoma • Ewing Sarcoma • Soft Tissue Sarcomas • Rhabdomyosarcoma • Non-Rhabo STS • Infantile fibrosarcoma • Desmoid tumor

  4. Osteosarcoma: Up front trials • Patients without metastases: Euramos (Neyssa Marina USA chair) • Metastatic: • Recently completed trial of feasibility of adding transtuzumab (herceptan) to MAP (David Ebb) • Plan to incorporate bisphosfonates (zolendronic acid) into MAP background

  5. Osteosarcoma-Treatment at First Pulmonary Relapse: Inhaled GM-CSF (Arndt PI) • For patients with bilateral mets • Resect one side • 2 cycles GM-CSF • Resect other side- measure Fas/FasL in tumor • Also using for patients with unilateral disease • Disease free interval will be measured

  6. Ewing Sarcoma: Upfront treatment • Patients without metastases • Still analyzing dose compression trial (Rick Womer) • Next trial will incorporate topotecan/cyclophosphamide pair (Mason Bond) • Patients with metastases • EuroEwings: pulmonary mets (Doug Hawkins) • Metranomic therapy (Judy Felgenhauer)

  7. Schema: AEWS0031 (Mason Bond) VAdCA alt with I/E R A N D O M I Z E Duration 48 weeks VAdCA alt with I/E alt with V/T/C Duration 48 weeks

  8. Metronomic Therapy for Patients Presenting with Extensive Metastases • PI Felgenhauer • Standard therapy backbone (Vcr, Dox, Cyclophos alt with ifosfamide/etoposide) • Overlay of • Celecoxib 250 mg/m2 per day • Vinblastine 1 mg/m2 three times weekly • Objective is feasibility of regimen, estimation of EFS, assessment of surrogate angiogen. markers • Will reach accrual soon

  9. Concept for Next Trial for Patients with Extensive Metastases • Pilot to look at addition of irinotecan/temozolomide to standard therapy • Goal will be feasibility • Also considering bevacizumab randomization

  10. Rhabdomyosarcoma-Up Front Patients Without Metastases • Low Risk (David Waterhouse PI) Emb only • 4 courses VAC for all patients; Subset A stops • Stage 1, clinical group I/II & orbital group III, stage 2 clinical group I, II • 4 more VA courses for subset B • Stage 1, group III not orbit or stage 3 clinical group I/II • Intermediate risk (Doug Hawkins PI) • Randomize VAC vs VAC alternating with Vincristine/Irinotecan

  11. RhabdomyosarcomaPatients Presenting with Metastases • Brenda Weigel PI • Intensive regimen • Rx • Vincristine, irinotecan window • VDC • IE • Iriniotecan/vcr during radiation

  12. NRSTS • NRSTS: Risk based rx, Sherry Spunt PI • 7 cycles ID • Infantile fibrosarcoma, Mignon Loh PI • VAC, stopping C before infertility likely • Convert non-operable to operable • Desmoid tumors, Steve Skapek PI • f/u to mtx/vbl study • Sulindac and tamoxifen

  13. Biology Trials • Collecting specimens at diagnosis for each tumor type • Collection process has been extremely successful • Committees review concepts for use of the tissue